Table 3 Baseline and ongoing data collection

Screening visit

• Age, sex, target weight, duration on dialysis, cause of end-stage kidney disease, vascular access type

• Serum calcium, phosphate, parathyroid hormone, Kt/V, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D

• Medication use

• GODIN leisure-time activity questionnaire

• DASI aerobic capacity questionnaire

Baseline study visit

• Serum calcium, phosphate, parathyroid hormone, Kt/V, 25OHD level, 1,25-dihydroxy vitamin D level, catecholamines

• Renin, aldosterone, angiotensin II

• Delivered dose of dialysis (Kt/V)

• Power spectral analysis (LF, HF, LF:HF) and time domain (SDNN, SDANN, pNN50%) HRV parameters

Study visits every 6 weeks up to 24 weeks

• Serum calcium, serum phosphate, parathyroid hormone, 25OHD, 1,25-dihydroxy-vitamin D, catecholamines

• Renin, aldosterone, angiotensin II

• Delivered dose of dialysis (Kt/V)

• Power spectral analysis (LF, HF, LF:HF) and time domain (SDNN, SDANN, pNN50%) HRV parameters